Jiang, Bo
Qi, Junyuan
Song, Yuqin
Li, Zengjun
Tu, Meifeng
Ping, Lingyan
Liu, Zongliang
Bao, Hanying
Xu, Zusheng
Qiu, Lugui
Clinical trials referenced in this document:
Documents that mention this clinical trial
Phase 1 clinical trial of the PI3Kδ inhibitor YY-20394 in patients with B-cell hematological malignancies
https://doi.org/10.1186/s13045-021-01140-z
Funding for this research was provided by:
Shanghai Yingli Pharmaceutical Co., Ltd.
Biomedical Science and Technology Support Program of Shanghai Science and Technology Commission (18431904700)
Article History
Received: 1 June 2021
Accepted: 12 August 2021
First Online: 23 August 2021
Declarations
:
: The Institutional Review Boards of the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Affiliated Cancer Hospital of Peking University involved gave approval for the study protocols and all enrolled patients gave their consent.
: Not applicable.
: Prof. Lugui Qiu and Prof. Junyuan Qi received research grants from Shanghai Yingli Pharmaceutical Co., Ltd.; Prof. Bo Jiang, Prof. Lugui Qiu, Prof. Junyuan Qi, Prof. Yuqin Song, Prof. Meifeng Tu, Prof. Lingyan Ping, Prof. Zengjun Li received consulting fees from Shanghai Yingli Pharmaceutical Co., Ltd; Dr. Zusheng Xu is a shareholder of Shanghai Yingli Pharmaceutical Co., Ltd; Dr. Hanying Bao and Mr. Zongliang Liu are employees of Shanghai Yingli Pharmaceutical Co., Ltd.